Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model


Jazz Pharmaceuticals



) pushed the Drugs industry higher today making it today's featured drugs winner. The industry as a whole closed the day down 1.1%. By the end of trading, Jazz Pharmaceuticals rose $1.15 (2.1%) to $55.61 on light volume. Throughout the day, 568,260 shares of Jazz Pharmaceuticals exchanged hands as compared to its average daily volume of 760,400 shares. The stock ranged in a price between $53.21-$55.81 after having opened the day at $54.09 as compared to the previous trading day's close of $54.46. Other companies within the Drugs industry that increased today were:




), up 9.3%,

Reliv' International



), up 6.4%,

Aegerion Pharmaceuticals



), up 5.5%, and




), up 5%.

  • ACTIVE STOCK TRADERS: Get full access to Jim Cramer's thoughts for less than $3/week - sometimes before he says them on TV! Start with a 14-Day Free Trial.

Jazz Pharmaceuticals Public Limited Company, a specialty biopharmaceutical company, focuses on the identification, development, and commercialization of pharmaceutical products to meet unmet medical needs. Jazz Pharmaceuticals has a market cap of $3.19 billion and is part of the health care sector. The company has a P/E ratio of 23.1, equal to the average drugs industry P/E ratio and above the S&P 500 P/E ratio of 17.7. Shares are up 41% year to date as of the close of trading on Monday. Currently there are nine analysts that rate Jazz Pharmaceuticals a buy, no analysts rate it a sell, and none rate it a hold.

TheStreet Ratings rates Jazz Pharmaceuticals as a


. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, solid stock price performance, good cash flow from operations and expanding profit margins. We feel these strengths outweigh the fact that the company has had sub par growth in net income.

On the negative front,

ADVENTRX Pharmaceuticals



), down 10.2%,

Keryx Biopharmaceuticals



), down 9.4%,




), down 9.1%, and




), down 6.9%, were all laggards within the drugs industry with




) being today's drugs industry laggard.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider

SPDR S&P Pharmaceuticals ETF



) while those bearish on the drugs industry could consider

ProShares UltraShort Nasdaq Biotech




FREE from Real Money's Jim Cramer: Winners and Losers Election 2012 - Steps to take NOW so you can profit no matter who is in charge!

Free download now